

## Electronic Supporting Information

Use of the Dehydrophos Biosynthetic Enzymes to Prepare Antimicrobial Analogs of  
Alaphosphin

Despina J. Bougioukou,<sup>1,§</sup> Chi P. Ting,<sup>1,§</sup> Spencer C. Peck,<sup>1,2</sup> Subha Mukherjee,<sup>2</sup> and  
Wilfred A. van der Donk<sup>1-3\*</sup>

<sup>1</sup>Institute for Genomic Biology, University of Illinois at Urbana-Champaign, 1206 West  
Gregory Drive, Urbana, IL 61801

<sup>2</sup>Department of Chemistry, University of Illinois at Urbana-Champaign, 600 South  
Mathews Ave, Urbana, IL 61801


<sup>3</sup>Howard Hughes Medical Institute

Phone: (217) 244 5360; fax: (217) 244 8533


\*Author to whom correspondence should be addressed

§ These authors contributed equally to this study


E-mail: vddonk@illinois.edu



**Figure S1.** General procedure<sup>1</sup> and overall yields for the preparation of phosphonate dipeptides as authentic standards.




**Figure S2.** Agar diffusion growth inhibition assay for phosphonodipeptides (1-12, 30  $\mu\text{g}$  each) against the indicator strain *E. coli* ATCC 25922. Kanamycin (Kan, 30  $\mu\text{g}$ ) and water ( $\text{H}_2\text{O}$ ) were used as positive and negative controls respectively. The experiment was performed once.




**Figure S3.**  $^{31}\text{P}$  NMR analysis of DhpH-C activity with L-Leu and L-Ala(P). **a.** Complete reaction containing 5 mM Ala(P), 6 mM Leu, 6 mM ATP, 1.5 mg total tRNA from *E. coli*, 6  $\mu\text{M}$  LeuRS (triple mutant), 10 U TIPP, and DhpH-C (50  $\mu\text{M}$ ) in 100 mM Na-HEPES, 10 mM KCl, 20 mM  $\text{MgCl}_2$ , pH 7.5. Arrow indicates the expected product. **b.** Control reaction without DhpH-C shows no product formation. Similarly, all reactions in Figures 7 and 8 required DhpH-C.

## Characterization of synthetic compounds




Following the general procedure, L-Ala(P) (288 mg, 2.3 mmol, 1 equiv) and Z-L-Leu (610 mg, 2.3 mmol, 1 equiv) afforded 191 mg (35%) of compound **1** as a white solid.

$^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.18 (dq,  $J = 14.8, 7.2$  Hz, 1H), 4.00 (t,  $J = 6.9$  Hz, 1H), 1.83 – 1.75 (m, 1H), 1.76 – 1.68 (m, 2H), 1.36 (dd,  $J = 15.9, 7.4$  Hz, 3H), 0.97 (dd,  $J = 10.4, 6.3$  Hz, 6H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  169.5, 52.0, 43.4 (d,  $J = 153.4$  Hz), 39.7, 23.6, 21.6, 20.9, 14.7;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  19.4; HRMS (ESI) calcd for  $[\text{C}_8\text{H}_{20}\text{N}_2\text{O}_4\text{P}_1]^+$  (M+H) $^+$ :  $m/z$  239.1161, found 239.1157.




Following the general procedure, aminomethylphosphonate (58 mg, 0.52 mmol, 1 equiv) and Z-L-Leu (133 mg, 0.5 mmol, 1 equiv) afforded 100 mg (89%) of compound **2** as a clear oil.  $^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.02 (t,  $J = 7.2$  Hz, 1H), 3.58 (t,  $J = 14.1$  Hz, 1H), 3.23 (t,  $J = 13.4$  Hz, 1H), 1.78 (d,  $J = 7.2$  Hz, 1H), 1.75 – 1.65 (m, 2H), 0.97 (dd,  $J = 10.1, 6.5$  Hz, 6H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  169.8, 52.2, 39.6, 38.1 (d,  $J = 141.7$  Hz), 23.8, 21.6, 21.0;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  14.7; HRMS (ESI) calcd for  $[\text{C}_7\text{H}_{18}\text{N}_2\text{O}_4\text{P}_1]^+$  (M+H) $^+$ :  $m/z$  225.1004, found 225.1001.




Following the general procedure, aminophenylmethylphosphonate (434 mg, 2.4 mmol, 1 equiv) and Z-L-Leu (610 mg, 2.3 mmol, 1 equiv) afforded 440 mg (65%) of compound **3** as a white solid as a 1.5:1 mixture of diastereomers. major isomer:  $^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  7.29 – 7.12 (m, 5H), 5.06 (d,  $J = 23.4$ , 1H), 3.93 (dd,  $J = 8.3, 6.0$  Hz, 1H), 1.68 – 1.36 (m, 2H), 1.32 – 1.20 (m, 1H), 0.67 (d,  $J = 6.7$  Hz, 3H), 0.62 (d,  $J = 6.7$  Hz, 3H);  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  15.6. minor isomer:  $^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  7.29 – 7.12 (m, 5H), 5.02 (d,  $J = 20.4$  Hz, 1H), 3.93 (dd,  $J = 8.3, 6.0$  Hz, 1H), 1.68 – 1.36 (m, 2H), 1.08 (td,  $J = 7.2, 2.4$  Hz, 1H), 0.79 (dd,  $J = 14.0, 6.6$ , 6H);  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  16.0. both isomers:  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  169.9, 169.9, 137.1, 136.9, 128.6, 128.4, 127.6, 127.6, 127.4, 127.4, 127.4, 127.2, 127.2, 54.1 (d,  $J = 142.2$  Hz), 53.5 (d,  $J = 141.6$

Hz), 52.0, 51.9, 39.8, 39.6, 23.8, 23.7, 21.8, 21.5, 21.1, 20.9; HRMS (ESI) calcd for  $[C_{13}H_{22}N_2O_4P_1]^+$  (M+H) $^+$ : m/z 301.1317, found 301.1316.




Following the general procedure, L-Val(P) (61 mg, 0.4 mmol, 1 equiv) and Z-L-Leu (106 mg, 0.4 mmol, 1 equiv) afforded 22 mg (21%) of compound **4** as a white solid.

$^1H$  NMR (600 MHz,  $D_2O$ )  $\delta$  4.11 (t,  $J = 7.0$  Hz, 1H), 3.92 (dd,  $J = 17.1, 5.5$  Hz, 1H), 2.22 – 2.12 (m, 1H), 1.86 – 1.78 (m, 1H), 1.78 – 1.70 (m, 2H), 1.02 – 0.96 (m, 12H);  $^{13}C$  NMR (150 MHz,  $D_2O$ )  $\delta$  170.1 (d,  $J = 5.8$  Hz), 54.0 (d,  $J = 145.4$  Hz), 52.0, 39.8, 28.8 (d,  $J = 2.4$  Hz), 23.6, 21.8, 20.7, 20.3 (d,  $J = 9.9$  Hz), 17.7 (d,  $J = 5.7$  Hz);  $^{31}P$  NMR (243 MHz,  $D_2O$ )  $\delta$  17.1; HRMS (ESI) calcd for  $[C_{10}H_{24}N_2O_4P_1]^+$  (M+H) $^+$ : m/z 267.1474, found 267.1476.




Following the general procedure, 1-aminopropylphosphonate (56 mg, 0.4 mmol, 1 equiv) and Z-L-Leu (106 mg, 0.4 mmol, 1 equiv) afforded 17 mg (17%) of compound **5** as a white solid as a 1.1:1 mixture of diastereomers.

$^1H$  NMR (600 MHz,  $D_2O$ )  $\delta$  4.31 (q,  $J = 7.2$  Hz, 1H), 4.17 – 4.09 (m, 1H), 4.02 (t,  $J = 7.5$ , 1H), 3.99 – 3.90 (t,  $J = 14.9$ , 1H), 1.95 – 1.84 (m, 2H), 1.83 – 1.63 (m, 4H), 1.61 – 1.54 (m, 2H), 1.16 (t,  $J = 7.2$ , 1H), 1.27 – 1.22 (m, 1H), 1.01 – 0.91 (m, 18H);  $^{13}C$  NMR (150 MHz,  $D_2O$ )  $\delta$  170.0, 169.9, 52.3, 51.4, 50.5 (d,  $J = 147.1$  Hz), 39.7, 38.7, 23.9, 22.6, 21.4, 21.2, 20.9, 13.8, 13.1, 10.6, 10.5;  $^{31}P$  NMR (243 MHz,  $D_2O$ )  $\delta$  17.94; HRMS (ESI) calcd for  $[C_9H_{22}N_2O_4P_1]^+$  (M+H) $^+$ : m/z 253.1317, found 253.1319.




Following the general procedure, 1-aminoethylphosphinic acid (44 mg, 0.4 mmol, 1 equiv) and Z-L-Leu (106 mg, 0.4 mmol, 1 equiv) afforded 31 mg (35%) of compound **6** as a white solid as a 1.8:1 mixture of diastereomers.

$^1H$  NMR (600 MHz,  $D_2O$ )  $\delta$  6.8 (d,  $J = 519.4$  Hz, 1H), 4.1 – 3.9 (m, 2H), 1.8 – 1.6 (m, 3H), 1.4 – 1.2 (m, 3H), 1.0 – 0.9 (m, 6H);  $^{13}C$  NMR (150 MHz,  $D_2O$ )  $\delta$  169.6 (d,  $J = 4.0$  Hz), 169.2 (d,  $J = 5.3$  Hz), 52.2, 52.1, 45.9 (d,  $J = 99.8$  Hz), 44.4, 43.4, 39.7, 39.6, 23.9, 23.8, 21.5, 21.5, 21.2, 21.2, 15.1, 11.9;  $^{31}P$  NMR (243 MHz,  $D_2O$ )  $\delta$  25.4, 18.7; HRMS (ESI) calcd for  $[C_8H_{20}N_2O_3P_1]^+$  (M+H) $^+$ : m/z 223.1212, found 223.1208.




Following the general procedure, L-Ala(P) (25 mg, 0.2 mmol, 1 equiv) and Z-L-isoleucine (53 mg, 0.2 mmol, 1 equiv) afforded 35 mg (78%) of compound **7** as a clear oil.

$^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.3 (dq,  $J = 14.7, 7.4$  Hz, 1H), 3.8 (d,  $J = 5.7$  Hz, 1H), 2.0 – 1.9 (m, 1H), 1.6 – 1.5 (m, 1H), 1.3 (dd,  $J = 16.6, 7.4$  Hz, 3H), 1.3 – 1.2 (m, 1H), 1.0 (d,  $J = 6.9$  Hz, 3H), 0.9 (t,  $J = 7.4$  Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  168.3, 57.8, 42.7 (d,  $J = 154.3$  Hz), 36.4, 24.0, 14.2, 13.8, 10.4;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  22.3; HRMS (ESI) calcd for  $[\text{C}_8\text{H}_{20}\text{N}_2\text{O}_4\text{P}_1]^+$  (M+H) $^+$ :  $m/z$  239.1161, found 239.1158.




Following the general procedure, L-Ala(P) (25 mg, 0.2 mmol, 1 equiv) and Z-L-valine (50 mg, 0.2 mmol, 1 equiv) afforded 18 mg (40%) of compound **8** as a clear oil. For the purification 0.1% trifluoroacetic acid in  $\text{H}_2\text{O}$  was used as a mobile phase for C18 reversed-phase chromatography.

$^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.26 – 4.19 (m, 1H), 3.80 (d,  $J = 8.3$  Hz, 1H), 2.28 – 2.20 (m, 1H), 1.37 (dd,  $J = 16.3, 7.1$  Hz, 3H), 1.06 (d,  $J = 6.7$  Hz, 6H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  168.3 (d,  $J = 5.3$  Hz), 162.9 (q,  $J = 34.8$  Hz), 116.2 (q,  $J = 290.0$  Hz), 58.7, 43.1 (d,  $J = 151.9$  Hz), 30.0, 17.4, 16.8, 14.6;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  20.7; HRMS (ESI) calcd for  $[\text{C}_7\text{H}_{18}\text{N}_2\text{O}_4\text{P}_1]^+$  (M+H) $^+$ :  $m/z$  225.1004, found 225.1003.



Following the general procedure, L-Ala(P) (25 mg, 0.2 mmol, 1 equiv) and Z-L-alanine (45 mg, 0.2 mmol, 1 equiv) afforded 25 mg (64%) of compound **9** as a clear oil.


$^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.20 – 3.98 (m, 2H), 1.55 (d,  $J = 6.9$  Hz, 3H), 1.31 (dd,  $J = 14.7, 6.9$  Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  169.7, 49.3, 44.2 (d,  $J = 146.2$  Hz), 16.4, 15.4;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  18.1; HRMS (ESI) calcd for  $[\text{C}_5\text{H}_{14}\text{N}_2\text{O}_4\text{P}_1]^+$  (M+H) $^+$ :  $m/z$  197.0691, found 197.0689.



Following the general procedure, L-Ala(P) (25 mg, 0.2 mmol, 1 equiv) and Z-L-norvaline (50 mg, 0.2 mmol, 1 equiv) afforded 44 mg (98%) of compound **10** as a clear oil.


$^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.25 (dq,  $J = 15.0, 7.5$  Hz, 1H), 3.95 (t,  $J = 6.8$  Hz, 1H), 1.86 – 1.71 (m, 2H), 1.42 – 1.29 (m, 5H), 0.90 (t,  $J = 7.3$  Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )

$\delta$  169.2, 53.1, 42.7 (d,  $J = 153.8$  Hz), 32.9, 17.4, 14.2, 12.8;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  22.5; HRMS (ESI) calcd for  $[\text{C}_7\text{H}_{18}\text{N}_2\text{O}_4\text{P}_1]^+$  (M+H) $^+$ :  $m/z$  225.1004, found 225.1000.



Following the general procedure, L-Ala(P) (25 mg, 0.2 mmol, 1 equiv) and Z-L-norleucine (53 mg, 0.2 mmol, 1 equiv) afforded 39 mg (82%) of compound **11** as a white solid.

$^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.08 (dq,  $J = 14.8, 7.4$  Hz, 1H), 3.97 (t,  $J = 6.8$  Hz, 1H), 2.00 – 1.82 (m, 2H), 1.44 – 1.37 (m, 4H), 1.34 (dd,  $J = 14.9, 7.5$  Hz, 3H), 0.91 (t,  $J = 3.3$  Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  169.1 (d,  $J = 6.2$  Hz), 53.5, 43.9 (d,  $J = 148.3$  Hz), 30.5, 26.1, 21.5, 15.2, 12.9;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  18.5; HRMS (ESI) calcd for  $[\text{C}_8\text{H}_{20}\text{N}_2\text{O}_4\text{P}_1]^+$  (M+H) $^+$ :  $m/z$  239.1161, found 239.1158.



Following the general procedure, L-Ala(P) (25 mg, 0.2 mmol, 1 equiv) and Z-L-methionine (57 mg, 0.2 mmol, 1 equiv) afforded 8.0 mg (16%) of compound **12** as a clear oil.

$^1\text{H}$  NMR (600 MHz,  $\text{D}_2\text{O}$ )  $\delta$  4.22 (dq,  $J = 14.0, 7.4, 6.7$  Hz, 1H), 4.12 (t,  $J = 6.7$  Hz, 1H), 2.72 – 2.58 (m, 2H), 2.27 – 2.15 (m, 2H), 2.13 (s, 3H), 1.36 (dd,  $J = 16.5, 7.4$  Hz, 3H);  $^{13}\text{C}$  NMR (150 MHz,  $\text{D}_2\text{O}$ )  $\delta$  168.3 (d,  $J = 5.4$  Hz), 52.4, 43.3 (d,  $J = 151.5$  Hz), 30.0, 28.0, 14.5, 13.9;  $^{31}\text{P}$  NMR (243 MHz,  $\text{D}_2\text{O}$ )  $\delta$  20.7; HRMS (ESI) calcd for  $[\text{C}_7\text{H}_{18}\text{N}_2\text{O}_4\text{P}_1\text{S}_1]^+$  (M+H) $^+$ :  $m/z$  257.0725, found 257.0723.

## References

- 1.) V. Solodenko, T. Kasheva and V. Kukhar, Preparation of N-Acylated Phosphono-peptides with Free Phosphonic Group, *Syn. Comm.*, 1991, **21**, 1631-1641.

